Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tessera Diagnostics Inc.

This article was originally published in Start Up

Executive Summary

Tessera Diagnostics, founded in December 2000, is focusing on developing a group of protein markers for early detection of cancer. It's first indication is prostate cancer, and it has in-licensed a group of 14 markers from a family of proteins called NMPs for early detection of the disease. It believes some of these markers are specific and highly sensitive to the disease, and as a group they will provide better information than any test currently available.

You may also be interested in...



Overcoming Skepticism About Cancer Diagnostics

In cancer diagnostics skepticism and optimism exist side by side. This is evident from a growing dichotomy between the spurt of early research projects, fueled by new technologies and increased government spending, and the lack of investor interest. Despite a brutal financing market and past disappointments, a few start-ups determined to address the field's unmet needs are pursuing development of new markers and detection technologies and gaining momentum.

A Business in Cancer Susceptibility Testing?

Making money in cancer susceptibility testing has been tough; all eyes are on Myriad.

Diagnostic Destinies in Seattle

In one month, in Seattle, two diagnostics companies, generic glucose strip maker Polymer Technologies and osteoporosis test maker Ostex International, both saw their businesses radically changed by Johnson & Johnson--the first nearly destroyed, the second boosted.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

MT037211

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel